September 17 Product: Novartis Kisqali Indication : Breast cancer Novartis has approximately doubled the eligible patient population for its Kisqali in breast cancer, as the FDA greenlit a label expansion of the drug, in combination with an aromatase inhibitor, for earlier stages of the disease
Explore the potential of Glutathione shots and see lasting results as part of a healthy lifestyle
However, for some patients, TRT may lead to an increase in estrogen levels, which can cause unwanted side effects such as water retention, mood swings, and gynecomastia (breast tissue gr
doi: 10.7603/s40681-016-0009-1
With that being said the trial was 54.5% female, was relatively young, 34 years old, and had an average BMI of 37